United Therapeutics Posts Record $3.18B Revenue on Tyvaso DPI Growth
Event summary
- United Therapeutics reported $3.18B in 2025 revenue, up 11% YoY, marking its fourth consecutive year of record revenue.
- Tyvaso DPI sales surged 25% YoY to $1.29B, driven by patient growth and Medicare Part D benefit redesign.
- Net income rose to $1.33B, with $364.3M in Q4 2025 alone.
- Company repurchased $1B in common stock via accelerated share repurchase agreements in 2025.
- R&D expenses increased 14% YoY to $550M, focusing on manufactured organ and drug delivery technologies.
The big picture
United Therapeutics' strong 2025 performance underscores the strategic importance of Tyvaso DPI in its portfolio, particularly as regulatory changes like the Inflation Reduction Act reshape market dynamics. The company's sustained investment in R&D signals a long-term focus on transformative therapies, positioning it competitively in the rare disease and organ alternative sectors. However, maintaining growth momentum will depend on successful clinical trial outcomes and efficient cost management.
What we're watching
- Clinical Trial Outcomes
- The impact of ADVANCE OUTCOMES and TETON-1 clinical programs on future growth prospects.
- Regulatory Dynamics
- How Medicare Part D benefit redesign continues to influence Tyvaso DPI commercial utilization.
- Execution Risk
- Whether United Therapeutics can sustain double-digit revenue growth amid rising R&D and operational costs.
Related topics